行情

VRNA

VRNA

Verona Pharma
NASDAQ

实时行情|Nasdaq Last Sale

4.101
+0.044
+1.08%
交易中 11:50 10/15 EDT
开盘
3.950
昨收
4.057
最高
4.101
最低
3.950
成交量
3,740
成交额
--
52周最高
13.38
52周最低
3.650
市值
5,372.18万
市盈率(TTM)
-2.1715
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VRNA 新闻

  • 一文看懂谷歌秋季发布会:AI串联全家桶
  • 新浪科技.1小时前
  • 高盛表示已将持有的WeWork股权减记了8000万美元
  • 新浪美股.1小时前
  • 德国警告英国脱欧将推迟 协议不足以解决技术性问题
  • 新浪美股.2小时前
  • 美联储5400亿美元"扩表" 分析师警告:市场可能吃不消
  • 新浪美股.2小时前

更多

所属板块

生物技术和医学研究
+2.01%
制药与医学研究
+1.32%

热门股票

名称
价格
涨跌幅

VRNA 简况

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a dual inhibitor of the enzymes phosphodiesterase 3 and 4 (PDE3 and PDE4) that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. The Company is developing RPL554 in a nebulized formulation for the maintenance treatment of COPD patients and for the treatment of cystic fibrosis. It also is developing RPL554 as an add-on therapy to commonly used therapies for the treatment of acute exacerbations of COPD in the hospital setting. In addition to its nebulized formulation of RPL554, the Company is developing RPL554 in both dry powder inhaler (DPI) and metered dose inhaler (MDI) formulations for the maintenance treatment of COPD.
展开

Webull提供Verona Pharma Plc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。